Business Wire

CMR Surgical: Galaxy Care Becomes First Hospital in the World to Acquire the Versius Surgical Robotic System

16.10.2019 07:00:00 EEST | Business Wire | Press release

Share

CMR Surgical Ltd today announced that Galaxy Care Hospital in Pune, India, has become the first hospital in the world to procure Versius ® , a next-generation surgical robotic system. A range of surgical procedures have already been conducted using Versius® at the world-renowned centre for laparoscopy, including transthoracic, hysterectomies and myomectomies, under the leadership of Dr. Shailesh Puntambekar.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005940/en/

Galaxy Care is a well-established centre of excellence for laparoscopic surgery and the introduction of Versius ® will support the hospital to bring robotic-assisted laparoscopic surgery to more people. Dr Shailesh Puntambekar, Consultant Oncologist, Surgeon and Medical Director of Galaxy Care will lead the team using Versius ® . He is an international pioneer in surgery and renowned for his advanced laparoscopic skills. In addition to this, he is responsible for training laparoscopy to surgeons from all over the world, helping to bring the benefits of minimal access surgery to patients globally.

Dr Puntambekar has led the way in bringing surgical robotics to India, having performed robotic-assisted surgery in India for over a decade and will be responsible for the introduction of Versius ® to Galaxy Care. Versius ® as a next-generation surgical robotic system with its small form factor, versatility and portability has been designed to support surgeons to deliver the benefits of minimal access surgery to patients around the world.

“As an experienced surgeon in robotic assisted surgery I think that there is significant potential for Versius ® to further increase access to laparoscopic surgery for my patients, so it was a natural choice to acquire this system. Versius ® , as a small and cost-effective system is well suited for meeting the high surgical demand in India. We are excited to bring the next-generation surgical robot to India.” said Dr. Shailesh Puntambekar, Medical Director at Galaxy Care Hospital, Pune, India.

“Galaxy Care has become our first customer to acquire and use Versius ® and this is an important milestone in bringing the benefits of minimal access surgery to all. We are pleased to be working with a centre that has some of the best surgeons in the world, meeting a high surgical demand. It is important that we bring Versius ® to market responsibly and we are delighted to be working closely with Galaxy Care on the introduction of Versius ® in the hospital”, said Mark Slack, Chief Medical Officer, CMR Surgical.

The commercial introduction of Versius ® also marks the launch of the world’s first clinical registry for a surgical robotic system. The registry is part of CMR Surgical’s commitment to post-market surveillance as part of the IDEAL framework and a responsible introduction of a medical device. The clinical registry managed by CMR Surgical, working in partnership with customers is recording and monitoring the patient outcomes of all procedures conducted using the Versius ® Surgical Robotic System in order to ensure patient safety. Outcome measures being recorded include: operative time, length of stay, return to hospital within 30 days, and return to operating room within 24 hours.

In addition to the first global commercial deal taking place in India, the Versius® Surgical Robotic System is expected to be introduced in hospitals across Europe later in 2019.

---ENDS---

About the Galaxy Care Hospital, Pune, India

Galaxy Care Hospital located in Pune, India is a specialist centre in laparoscopic and Robotic cancer surgeries. It has the first and only robotic theatre in western and southern India. The hospital is led by Medical Director Dr. Shailesh Puntambekar who has performed a number of internationally acclaimed procedures including India’s first successful womb transplant as well as pioneering laparoscopic radical hysterectomy for early stage cervical cancer, known globally as the Pune technique. Galaxy Care is now associated with the Care Group of Hospitals, with a number of hospitals across India.

About the Clinical Registry

The clinical registry established by CMR Surgical, working in partnership with customers will support post-market surveillance for the Versius ® Surgical Robotic System. The clinical registry will be collecting the following clinical data on procedures conducted using Versius ® : patient demographics, surgical history, date of diagnosis, planned procedure, operative time, estimated blood loss, return to operating theatre within 24 hours, length of stay, return to hospital within 30 days, mortality at 90 days, any complications that may have occurred. All data is anonymised.

About the Versius® Surgical Robotic System

Versius® resets expectations of robotic surgery by providing a versatile system that is portable, transportable and affordable. This is made possible because of its elegant form factor, modular design and individually cart-mounted arms. Versius® can move between operating rooms and even hospitals/clinics and gives the surgical team excellent access to the patient at all times.

Biomimicking the human arm, Versius® allows surgeons the freedom of port placement, but with the benefits of small fully-wristed instruments. With 3D HD vision, easy-to adopt instrument control and a choice of ergonomic working positions, the new open surgeon console has the potential to reduce stress and fatigue and extend the careers of surgeons.

About CMR Surgical Limited

CMR Surgical is a British private limited company developing the next-generation universal robotic system, Versius®, for minimal access surgery. The company received the European CE Mark in March 2019 for the Versius® Surgical Robotic System.

The vision behind CMR Surgical is to make minimal access surgery universally accessible and affordable, transforming the existing market for surgical robotics while also addressing the six million people who still undergo open surgery each year.

Global annual revenues for robot-assisted minimal access surgery are presently approximately $4 billion and are anticipated to reach $20 billion by 2025.

CMR Surgical, formed in 2014, has its headquarters in Cambridge, United Kingdom and is backed by an international shareholder base of specialist and generalist investors.

The Company achieved the registration of its Quality Management System to ISO 13485:2016 by Underwriters Laboratories LLC® (UL), and the status as a UL Registered Firm, in September 2015.

For further information, please visit www.cmrsurgical.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

CMR Surgical
Patrick Pordage/ Sarah Ghabina
patrick.pordage@cmrsurgical.com/ sarah.ghabina@cmrsurgical.com
+44 (0)7864 922341 /+44 (0)7749 432373

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

The Bolivarian Republic of Venezuela Announces the Initiation of a Comprehensive Public Debt Restructuring Process13.5.2026 23:08:00 EEST | Press release

The Bolivarian Republic of Venezuela announces today its decision to initiate a comprehensive restructuring of its external public debt obligations. CONTEXT & RATIONALE Over the past decade, Venezuela's economy has been severely impacted by external shocks – from the end of the commodity super-cycle to foreign sanctions and COVID-19 – resulting in a sharp economic contraction, a protracted default since 2017, and a ballooning of public sector liabilities. The country nonetheless possesses a strong economic potential, including unique hydrocarbon and mineral endowments. A recovery is underway, and Venezuela is committed to accelerating it through a comprehensive reform agenda in support of growth, fiscal sustainability, monetary stabilization, and enhanced governance. Restoring public debt sustainability is central to this agenda: the current debt overhang constrains external financing, limits public investment capacity, and prevents full re-engagement with the international financial s

Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise13.5.2026 22:00:00 EEST | Press release

Boomi, the data activation company for AI, today announced it has signed a letter of intent to acquire Lunar.dev, an innovator in AI and MCP gateway. The proposed acquisition is expected to enrich the Boomi Enterprise Platform and Boomi Connect with advanced capabilities to govern and scale AI usage across enterprise systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513850557/en/ Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise As organizations move from AI experimentation to production, controlling how agents and AI applications interact with LLMs at scale has become critical. Lunar.dev addresses this need with an AI gateway that delivers granular, policy-driven control over AI interactions, with the visibility, security, and performance required for enterprise environments. These capabilities enable organizations to move from pilot to production with confiden

BeOne Medicines’ BEQALZI ™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma13.5.2026 20:27:00 EEST | Press release

BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™(bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. BEQALZI was designed to enhance BCL2 inhibition—with greater potency, selectivity, and a pharmacologic profile with potential to improve efficacy, tolerability, and convenience over others in the class. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513542161/en/ BeOne Medicines' flagship U.S. biologics manufacturing and clinical R&D facility at the Princeton West Innovation Campus in Hopewell, N.J. Michael Wang, M.D., Global Principal Investigator

Boomi Unveils Innovations That Power the Agentic Enterprise13.5.2026 17:30:00 EEST | Press release

Boomi, the data activation company for AI, today announced a major expansion of the Boomi Enterprise Platform at Boomi World 2026, introducing new capabilities across orchestrated agentic workflows, agentic engineering, governed agent connectivity, grounded agent context, and localized agent infrastructure. Together, these innovations are designed to power the agentic enterprise — where agents and humans work together to drive action and operationalize AI at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513996223/en/ Boomi Unveils Innovations That Power the Agentic Enterprise The enterprise has reached a defining moment as AI becomes the primary interface for work and MCP emerges as the new standard. While the shift toward a headless, agentic enterprise is inevitable, this vision is colliding with skyrocketing cloud costs and trapped data. For many, layering agents onto a fragmented landscape only magnifies govern

Boomi and Couchbase Partner to Power Enterprise AI Agents with Trusted Recollection, Connectivity, and Governance13.5.2026 17:30:00 EEST | Press release

Boomi, the data activation company for AI, and Couchbase, Inc., the operational data platform for AI, today announced a partnership through which the two companies are collaborating closely to accelerate AI pilots to production. The companies will co-engineer solutions that give customers a production-ready foundation for agentic AI, combining Boomi's connectivity, runtime, and governance for AI agents with Couchbase's scalable recollection and vector capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513350337/en/ Enterprises deploying AI agents today face a common challenge: while agents perform well in pilots, they struggle to scale due to inconsistent access to trusted context, recollection, and real-time business data. Lack of governance, auditability, and operational control drives up compute costs while diminishing productivity and revenue. “2026 is the year organizations move from AI experimentation to a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye